SiRNA and cancer immunotherapy

Immunotherapy

Volumn 4, Issue 9, 2012, Pages 907-917

  Ghafouri Fard, Soudeh ^a   Ghafouri Fard, Somayyeh ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cancer immunotherapy; immune evasion; immune surveillance; RNAi; siRNA

Indexed keywords

BORTEZOMIB; CANCER VACCINE; DENDRITIC CELL VACCINE; FANG; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; SHORT HAIRPIN RNA; SIRNA 027; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLONAL ANERGY; DENDRITIC CELL; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LIPOSOMAL DELIVERY; LIVER CANCER; LYMPH NODE BIOPSY; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RNA INTERFERENCE; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DENDRITIC CELLS; GENE SILENCING; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 84867347162     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.87     Document Type: Review

References (75)

1. Ghafouri-Fard S, Ghafouri-Fard S. Immunotherapy in nonmelanoma skin cancer. Immunotherapy 4(5), 499-510 (2012).
2. Mullen CA, Schreiber H. Tumor growth and evasion of immune destruction: UV-induced tumors as a model. Surv. Immunol. Res. 4(4), 264-270 (1985). (Pubitemid 16079194)
3. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. 22(6), 1136-1151 (2004). (Pubitemid 41095048)
4. Conroy H, Galvin KC, Higgins SC, Mills KH. Gene silencing of TGF-b1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells. Cancer Immunol. Immunother. 61(3), 425-431 (2012).
5. Mao CP, Hung CF, Wu TC. Immunotherapeutic strategies employing RNA interference technology for the control of cancers. J. Biomed. Sci. 14(1), 15-29 (2007).
6. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2(4), 279-289 (1990). (Pubitemid 120029588)
7. Romano N, Macino G. Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences. Mol. Microbiol. 6(22), 3343-3353 (1992).
8. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6(9), 1130-1146 (2011).
9. Devi GR. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 13(9), 819-829 (2006).
10. Schlee M, Hornung V, Hartmann G. siRNA and isRNA: two edges of one sword. Mol. Ther. 14(4), 463-470 (2006). (Pubitemid 44296098)
11. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 19(2), 89-102 (2009).
12. Forsbach A, Müller C, Montino C et al. Impact of delivery systems on siRNA immune activation and RNA interference. Immunol. Lett. 141(2), 169-180 (2012).
13. Khairuddin N, Gantier MP, Blake SJ et al. siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol. Cell Biol. 90(2), 187-196 (2012).
14. Poeck H, Besch R, Maihoefer C et al. 5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14(11), 1256-1263 (2008).
15. Warashina S, Nakamura T, Harashima H. A20 silencing by lipid envelope-type nanoparticles enhances the efficiency of lipopolysaccharide- activated dendritic cells. Biol. Pharm. Bull. 34(8), 1348-1351 (2011).
16. Hornung V, Guenthner-Biller M, Bourquin C et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11(3), 263-270 (2005). (Pubitemid 40460553)
17. Goodchild A, Nopper N, King A et al. Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol. 10, 40 (2009).
18. Kleinman ME, Yamada K, Takeda A et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452(7187), 591-597 (2008). (Pubitemid 351483358)
19. Yen MC, Lin CC, Chen YL et al. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin. Cancer Res. 15(2), 641-649 (2009).
20. Huang TT, Yen MC, Lin CC et al. Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. Cancer Sci. 102(12), 2214-2220 (2011).
21. Alshamsan A, Haddadi A, Hamdy S et al. STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response. Mol. Pharm. 7(5), 1643-1654 (2010).
22. Naka T, Narazaki M, Hirata M et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 387(6636), 924-929 (1997). (Pubitemid 27289596)
23. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22(12), 1546-1553 (2004). (Pubitemid 40039457)
24. Song XT, Evel-Kabler K, Rollins L et al. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med. 3(1), e11 (2006).
25. Mao CP, Wu TC. Inhibitory RNA molecules in immunotherapy for cancer. Methods Mol. Biol. 623, 325-339 (2010).
26. Zhang J, Yu J, Yang L et al. Enhanced activation of human dendritic cells by silencing SOCS1 and activating TLRs simultaneously. Cancer Immunol. Immunother. doi:10.1007/s00262-012-1218-4 (2012) (Epub ahead of print).
27. Kortylewski M, Swiderski P, Herrmann A et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27(10), 925-932 (2009).
28. Song XT, Evel-Kabler K, Shen L, Rollins L, Huang XF, Chen SY. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med. 14(3), 258-265 (2008). (Pubitemid 351347913)
29. Breckpot K, Aerts-Toegaert C, Heirman C et al. Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J. Immunol. 182(2), 860-870 (2009).
30. Shi L, Luo K, Xia D et al. DigR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses. Blood 108(8), 2678-2686 (2006).
31. Stallwood Y, Briend E, Ray KM et al. Small interfering RNA-mediated knockdown of notch ligands in primary CD4+ T cells and dendritic cells enhances cytokine production. J. Immunol. 177(2), 885-895 (2006). (Pubitemid 44036589)
32. Karwacz K, Bricogne C, MacDonald D et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol. Med. 3(10), 581-592 (2011).
33. Karwacz K, Arce F, Bricogne C, Kochan G, Escors D. PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy. Oncoimmunology 1(1), 86-88 (2012).
34. Hobo W, Maas F, Adisty N et al. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood 116(22), 4501-4511 (2010).
35. Liu G, Ng H, Akasaki Y et al. Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur. J. Immunol. 34(6), 1680-1687 (2004). (Pubitemid 39256050)
36. Peng S, Kim TW, Lee JH et al. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum. Gene Ther. 16(5), 584-593 (2005). (Pubitemid 40740926)
37. Yi H, Guo C, Yu X et al. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity. Cancer Res. 71(21), 6611-6620 (2011).
38. Morris K, Castanotto D, Al-Kadhimi Z, Jensen M, Rossi J, Cooper LJ. Enhancing siRNA effects in T cells for adoptive immunotherapy. Hematology 10(6), 461-467 (2005). (Pubitemid 43123469)
39. Skapenko A, Leipe J, Niesner U et al. GATA-3 in human T cell helper type 2 development. J. Exp. Med. 199(3), 423-428 (2004). (Pubitemid 38252054)
40. Yu Y, Wu H, Tang Z, Zang G. CTLA4 silencing with siRNA promotes deviation of Th1/Th2 in chronic hepatitis B patients. Cell Mol. Immunol. 6(2), 123-127 (2009).
41. Dotti G, Savoldo B, Pule M et al. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 105(12), 4677-4684 (2005). (Pubitemid 40807289)
42. Catalano A, Caprari P, Moretti S, Faronato M, Tamagnone L, Procopio A. Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 107(8), 3321-3329 (2006).
43. Huang B, Zhao J, Li H et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65(12), 5009-5014 (2005). (Pubitemid 40827306)
44. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27(2), 218-224 (2008).
45. Tang D, Yuan Z, Xue X et al. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int. J. Cancer 130(10), 2337-2348 (2012).
46. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203(7), 1651-1656 (2006). (Pubitemid 44036269)
47. Zheng X, Koropatnick J, Li M et al. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J. Immunol. 177(8), 5639-5646 (2006). (Pubitemid 44527639)
48. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66(11), 5527-5536 (2006). (Pubitemid 43927099)
49. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer. 8(8), 579-591 (2008).
50. Chen Z, Varney ML, Backora MW et al. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res. 65(19), 9004-9011 (2005). (Pubitemid 41377392)
51. Shibata MA, Morimoto J, Shibata E, Otsuki Y. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther. 15(12), 776-786 (2008).
52. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest. New Drugs 21(1), 21-32 (2003). (Pubitemid 36628482)
53. Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin. Dev. Immunol. 2011, 609579 (2011).
54. Arce F, Breckpot K, Stephenson H et al. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum. 63(1), 84-95 (2011).
55. Li Y, Yang K, Mao Q, Zheng X, Kong D, Xie L. Inhibition of TGF-beta receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase. Int. Urol. Nephrol. 42(2), 315-323 (2010).
56. Wei H, Liu P, Swisher E et al. Silencing of the TGF-b1 gene increases the immunogenicity of cells from human ovarian carcinoma. J. Immunother. 35(3), 267-275 (2012).
57. Singh A, Qin H, Fernandez I et al. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. J. Control. Release 155(2), 184-192 (2011).
58. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. 149(1), 129-142 (1996). (Pubitemid 26230985)
59. Bellone S, Roque D, Cocco E et al. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. Br. J. Cancer 106(9), 1543-1550 (2012).
60. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109(11), 4839-4845 (2007). (Pubitemid 46827780)
61. de Carvalho F, Costa ET, Camargo AA et al. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines. PLoS ONE 6(11), e27707 (2011).
62. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch. Iran. Med. 12(4), 395-404 (2009).
63. Shen H, Sun T, Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther. 19(6), 367-373 (2012).
64. Senzer N, Barve M, Kuhn J et al. Phase I trial of "bi-shRNAi(furin)/ GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol. Ther. 20(3), 679-686 (2012).
65. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19(1), 60-71 (2012).
66. Judge AD, Robbins M, Tavakoli I et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119(3), 661-673 (2009).
67. Okamoto M, Furuichi S, Nishioka Y et al. Expression of Toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 64(15), 5461-5470 (2004). (Pubitemid 39006570)
68. Gao K, Huang L. Nonviral methods for siRNA delivery. Mol. Pharm. 6(3), 651-658 (2009).
69. Zimmermann TS, Lee AC, Akinc A et al. RNAi-mediated gene silencing in non-human primates. Nature 441(7089), 111-114 (2006).
70. Devi GR. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 13(9), 819-829 (2006).
71. van der Worp HB, Howells DW, Sena ES et al. Can animal models of disease reliably inform human studies? PLoS Med. 7(3), e1000245 (2010).
72. Hong H, Zhang Y, Cai W. In vivo imaging of RNA interference. J. Nucl. Med. 51(2), 169-172 (2010).
73. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499-511 (2004). (Pubitemid 38931765)
74. Basith S, Manavalan B, Lee G, Kim SG, Choi S. Toll-like receptor modulators: a patent review (2006-2010). Expert Opin Ther. Pat. 21(6), 927-944 (2011).
75. Töpfer K, Kempe S, Müller N et al. Tumor evasion from T cell surveillance. J. Biomed. Biotechnol. 2011, 918471 (2011).